Clinical Experiences of Intravenous Hydralazine and Labetalol for Acute Treatment of Severe Hypertension in Pregnant Thai Women-Reference-Cited by-同舟云学术

Clinical Experiences of Intravenous Hydralazine and Labetalol for Acute Treatment of Severe Hypertension in Pregnant Thai Women

Published:2020-06-29 Issue:12 Volume:60 Page:1662-1670
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Chera‐Aree Pattraporn¹,Tengtrakulcharoen Pimrapat²,Leetheeragul Jarunee¹,Sampaojarean Urai¹,Surasereewong Supitchaya¹,Wataganara Tuangsit¹^ORCID

Affiliation:

1. Department of Obstetrics and Gynecology Faculty of Medicine Siriraj Hospital Bangkok Thailand

2. Department of Research and Development Faculty of Medicine Siriraj Hospital Bangkok Thailand

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1685

Reference71 articles.

1. ACOG

2. Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy;Rey E;CMAJ,1997

3. HYPERTENSION IN PREGNANCY: Current Concepts of Preeclampsia

4. Management and monitoring of severe preeclampsia

5. Mechanisms and Management of Hypertension in Pregnant Women

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenomics of Preeclampsia therapies: Current evidence and future challenges for clinical implementation;Best Practice & Research Clinical Obstetrics & Gynaecology;2024-02

2. Comparison of outcomes following intravenous magnesium compared with intravenous labetalol and oral nifedipine in 355 pregnant Han Chinese women with preeclampsia;Medicine;2023-11-17

3. Pharmaceutical administration for severe hypertension during pregnancy: Network meta-analysis;Frontiers in Pharmacology;2023-01-09

4. Pharmacokinetics and pharmacodynamics of MT-1207, a novel multitarget blocker of α1 receptor, 5-HT2A receptor, and calcium channel, in healthy subjects;Expert Opinion on Investigational Drugs;2021-03-03